Anito-cel Shows High Efficacy and Impressive Two-Year Survival Rates in Relapsed/Refractory Multiple Myeloma

New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.